113 related articles for article (PubMed ID: 31911857)
1. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
Saab S; Chang OS; Nagaoka K; Hung MC; Yamaguchi H
Am J Cancer Res; 2019; 9(12):2719-2729. PubMed ID: 31911857
[TBL] [Abstract][Full Text] [Related]
2. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance.
Lee JE; Park HS; Lee D; Yoo G; Kim T; Jeon H; Yeo MK; Lee CS; Moon JY; Jung SS; Kim JO; Kim SY; Park DI; Park YH; Lee JC; Oh IJ; Lim DS; Chung C
Biochem Biophys Res Commun; 2016 May; 474(1):154-160. PubMed ID: 27105908
[TBL] [Abstract][Full Text] [Related]
4. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
5. NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors.
McGowan M; Kleinberg L; Halvorsen AR; Helland Å; Brustugun OT
Genes Cancer; 2017 Mar; 8(3-4):497-504. PubMed ID: 28680534
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
8. DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.
Jimbo T; Hatanaka M; Komatsu T; Taira T; Kumazawa K; Maeda N; Suzuki T; Ota M; Haginoya N; Isoyama T; Fujiwara K
Oncotarget; 2019 Aug; 10(50):5152-5167. PubMed ID: 31497246
[TBL] [Abstract][Full Text] [Related]
9. Expression characteristics of AXL and YAP in non-small cell lung cancer and prognostic importance.
Zhao C; Tu S; Zhang F; Zhang X
Int J Clin Exp Pathol; 2018; 11(7):3357-3365. PubMed ID: 31949712
[TBL] [Abstract][Full Text] [Related]
10. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
11. Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.
Breitenecker K; Hedrich V; Pupp F; Chen D; Řezníčková E; Ortmayr G; Huber H; Weber G; Balcar L; Pinter M; Mikulits W
Front Oncol; 2023; 13():1238883. PubMed ID: 37746265
[TBL] [Abstract][Full Text] [Related]
12. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Yang CT; Jablons DM; You L
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466572
[TBL] [Abstract][Full Text] [Related]
13. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S; Seike M; Miyanaga A; Chiba M; Zou F; Takahashi A; Ishikawa A; Kunugi S; Noro R; Kubota K; Gemma A
Oncotarget; 2018 Jun; 9(43):27242-27255. PubMed ID: 29930762
[TBL] [Abstract][Full Text] [Related]
14. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
15. Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.
Vouri M; Croucher DR; Kennedy SP; An Q; Pilkington GJ; Hafizi S
Oncogenesis; 2016 Oct; 5(10):e266. PubMed ID: 27775700
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
17. Src mediates β-adrenergic receptor induced YAP tyrosine phosphorylation.
Wang W; Li W; Liu K; Niu X; Guan K; Jiang Y; Li Z; Dong E
Sci China Life Sci; 2020 May; 63(5):697-705. PubMed ID: 32246402
[TBL] [Abstract][Full Text] [Related]
18.
Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network.
Wu X; Wang L; Pearson NA; Renuse S; Cheng R; Liang Y; Mun DG; Madugundu AK; Xu Y; Gill PS; Pandey A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439388
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway.
Qiu C; Zheng H; Tao H; Yu W; Jiang X; Li A; Jin H; Lv A; Li H
Mol Cell Biochem; 2017 Sep; 433(1-2):149-159. PubMed ID: 28386842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
